Suppr超能文献

成人与老年胶质母细胞瘤患者的总生存和手术范围:一项基于人群的回顾性研究。

Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.

机构信息

Department of Neurosurgery, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.

出版信息

Wien Klin Wochenschr. 2011 Jun;123(11-12):364-8. doi: 10.1007/s00508-011-1577-4. Epub 2011 May 18.

Abstract

INTRODUCTION

The purpose of this retrospective population based study was to investigate the effect of the extent of surgery on overall survival in young versus adult glioblastoma patients in Vorarlberg/Austria during the last 4 years.

METHODS

Forty-eight patients (median age 62.5 years, ranging from 25-82 years, 19 female and 29 male) with histologically proven glioblastoma received surgery (16 biopsies, 18 partial and 14 complete resections) and postoperative chemo-irradiation with concomitant and adjuvant temozolomide. The median follow up of the patient population was 11.7 months (ranging from 3 to 36 months). Postoperative temporary morbidity was found in 5 out of 48 (10.4%) patients, and no mortality or permanent morbidity occurred. One infection led to revision surgery.

FINDINGS

Altogether, the 12/24 months overall survival was 54/20.2% with a median survival of 13.7 months. In younger patients (<65 yrs, median 57.5 yrs, 28 patients), the 12/24 months overall survival was 68.4/34.3% with 16.9 months median survival, in the elderly patients (>65 yrs, median 73 yrs, 20 patients) the 12/24 months overall survival was 28.8/5.8%, with 7.7 months median survival (Log-rank, p = 0.0005). Extent of surgery influenced overall survival of the adult group nearly significantly (biopsy versus complete resection: p = 0.06), but did not affect overall survival of the elderly (p = 0.5).

CONCLUSIONS

Overall survival of elderly glioblastoma patients treated with surgery and chemo-irradiation with concomitant and adjuvant temozolomide is significantly reduced compared to the younger patients. In addition, in the elderly the extent of surgery did not influence the prognosis in our population.

摘要

简介

本回顾性基于人群的研究旨在探讨在过去 4 年中,奥地利福拉尔贝格州(Vorarlberg)年轻和成年胶质母细胞瘤患者手术范围对总生存率的影响。

方法

48 例患者(中位年龄 62.5 岁,年龄 25-82 岁,女性 19 例,男性 29 例)经组织学证实为胶质母细胞瘤,接受手术(16 例活检,18 例部分切除,14 例完全切除)和术后放化疗,同时给予替莫唑胺辅助治疗。患者人群的中位随访时间为 11.7 个月(3-36 个月)。48 例患者中有 5 例(10.4%)出现术后暂时性并发症,无死亡或永久性并发症。1 例感染导致再次手术。

结果

总的来说,12/24 个月的总生存率为 54/20.2%,中位生存期为 13.7 个月。在年轻患者(<65 岁,中位年龄 57.5 岁,28 例)中,12/24 个月的总生存率为 68.4/34.3%,中位生存期为 16.9 个月,在老年患者(>65 岁,中位年龄 73 岁,20 例)中,12/24 个月的总生存率为 28.8/5.8%,中位生存期为 7.7 个月(对数秩检验,p=0.0005)。手术范围对成年组的总生存率有显著影响(活检与完全切除:p=0.06),但对老年组无显著影响(p=0.5)。

结论

接受手术和放化疗联合替莫唑胺辅助治疗的老年胶质母细胞瘤患者的总生存率明显低于年轻患者。此外,在老年人群中,手术范围对本研究人群的预后没有影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验